Stockscreener 앱 받기
39.51
7.22%
2.66
시간 외 거래:
39.45
-0.06
-0.15%
전일 마감가:
$36.85
열려 있는:
$38.31
하루 거래량:
13.72M
Relative Volume:
2.23
시가총액:
$15.20B
수익:
$4.99B
순이익/손실:
$-5.87B
주가수익비율:
-4.2257
EPS:
-9.35
순현금흐름:
$-3.98B
1주 성능:
-7.58%
1개월 성능:
-26.97%
6개월 성능:
-70.27%
1년 성능:
-48.31%
1일 변동 폭
$37.10
$39.77
1주일 범위
$35.80
$44.11
52주 변동 폭
$35.80
$170.47
모더나 Stock (MRNA) Company Profile
명칭
Moderna Inc
전화
(617) 714-6500
주소
325 BINNEY STREET, CAMBRIDGE
MRNA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| MRNA | 39.51 | 15.20B | 4.99B | -5.87B | -3.98B | -9.35 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
모더나 Stock (MRNA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-09-13 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2024-09-13 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-09-13 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-08-28 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2024-08-07 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-08-05 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | 다운그레이드 | HSBC Securities | Hold → Reduce |
| 2024-01-02 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2023-11-29 | 개시 | Canaccord Genuity | Hold |
| 2023-11-03 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2023-11-02 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2023-08-04 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-07-24 | 개시 | William Blair | Mkt Perform |
| 2023-07-14 | 개시 | HSBC Securities | Reduce |
| 2023-06-26 | 업그레이드 | UBS | Neutral → Buy |
| 2023-04-26 | 개시 | Guggenheim | Neutral |
| 2023-03-13 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | 개시 | RBC Capital Mkts | Outperform |
| 2023-02-24 | 다운그레이드 | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-12-14 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | 업그레이드 | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2022-02-01 | 업그레이드 | Redburn | Sell → Neutral |
| 2022-01-26 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2022-01-21 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-01-21 | 개시 | UBS | Neutral |
| 2021-12-07 | 개시 | Cowen | Market Perform |
| 2021-11-09 | 개시 | Wolfe Research | Outperform |
| 2021-10-22 | 개시 | Deutsche Bank | Sell |
| 2021-10-15 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-08-06 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | 재확인 | Jefferies | Hold |
| 2021-02-01 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-12-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-12-16 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | 다운그레이드 | Needham | Buy → Hold |
| 2020-11-23 | 개시 | Wells Fargo | Equal Weight |
| 2020-11-17 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | 개시 | SVB Leerink | Mkt Perform |
| 2020-07-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-07-13 | 개시 | Jefferies | Buy |
| 2020-06-30 | 개시 | Argus | Buy |
| 2020-06-08 | 개시 | Barclays | Overweight |
| 2020-04-30 | 개시 | BMO Capital Markets | Outperform |
| 2020-03-05 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | 재개 | BofA/Merrill | Buy |
| 2019-10-25 | 개시 | ROTH Capital | Buy |
| 2019-04-05 | 개시 | Chardan Capital Markets | Buy |
모두보기
모더나 주식(MRNA)의 최신 뉴스
Moderna Remains Confident Despite Political Concerns Over Vaccine Safety and HHS Nomination - AOL
Moderna (NASDAQ:MRNA) Sees Strong Trading VolumeHere's What Happened - MarketBeat
Moderna (NASDAQ:MRNA) Receives "Overweight" Rating from Piper Sandler - MarketBeat
Moderna's stock decline after RFK Jr's appointment makes an "attractive entry point": Piper Sandler - Seeking Alpha
Moderna (NASDAQ:MRNA) Raised to Buy at HSBC - MarketBeat
Analyst recommendations: Biogen, HP, Moderna, Shell... - Marketscreener.com
KBC Group NV Sells 56,297 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna, Inc. (NASDAQ:MRNA) Receives Average Rating of "Hold" from Analysts - MarketBeat
Health Care Down as RFK Fears Mount -- Health Care Roundup - Marketscreener.com
Moderna Inc. stock underperforms Friday when compared to competitors - MarketWatch
Pfizer, Moderna, BioNTech Take A Beating After Trump Taps Kennedy To Head Up HHS - Yahoo! Voices
Moderna, Pfizer pharma stock dips after RFK Jr. nominated to lead HHS - Healthcare Brew
Moderna Shares Are Dipping Today: What's Going On? - Benzinga
Health stocks are tumbling after Trump's appointment of vaccine skeptic RFK Jr. - Markets Insider
Moderna (NASDAQ:MRNA) Shares Gap DownHere's What Happened - MarketBeat
Moderna, Inc. (MRNA): Among 12 High Growth Large Cap Stocks to Buy Now - Yahoo Finance
First Week of July 2025 Options Trading For Moderna (MRNA) - Nasdaq
Moderna, Novavax stocks slide after Trump nominates Robert F. Kennedy Jr. to be top health official - Yahoo Finance
RFK Jr vow to purge FDA sets up collision with Big Pharma - Reuters.com
Moderna continues to be the most shorted among S&P 500 healthcare stocks in October - Seeking Alpha
Moderna, Lily, Novavax, and Pfizer stocks fall after Trump nominates RFK Jr. as health secretary - Fast Company
This is the One Reason Moderna, Novavax, and Drug Stocks Slumped - Baystreet.ca
Moderna (NASDAQ:MRNA) Coverage Initiated by Analysts at Wolfe Research - MarketBeat
WHO Calls Vaccines 'Absolutely Critical' As Trump's Appointment Of RFK Jr Pulls Pzifer, Moderna Stocks Downhill - Benzinga
Moderna, Novovax stocks slide after Trump nominates Robert F. Kennedy Jr. to be top health official - Yahoo Finance
Trump Taps Vaccine Skeptic RFK Jr. to Lead HHS. Moderna, Novavax Stock Slide. - Barron's
Moderna, Novavax Shares Slip After Trump Names RFK Jr. Health Chief Nominee - Wall Street Pit
Palantir, Moderna, Pfizer, Alibaba, Tesla: Why These 5 Stocks Are On Investors' Radars Today - Benzinga
Moderna, Pfizer Stocks Fall After Reports of RFK Jr. Nomination - The Wall Street Journal
Health Care Down Amid RFK Fears -- Health Care Roundup - Marketscreener.com
12 High Growth Large Cap Stocks to Buy Now - Insider Monkey
Vaccine-maker stocks like Moderna, Pfizer drop as Trump taps RFK Jr. to lead HHS - MarketWatch
Moderna Inc. stock underperforms Thursday when compared to competitors - MarketWatch
With RFK Jr. Set To Join Trump’s Team, Pfizer, Moderna, And Other Vaccine Stocks Slump - Times Now
Moderna stock touches 52-week low at $41.52 amid market challenges - Investing.com
mRNA Vaccine and Therapeutics Market 2024-2031: Global - openPR
Sumitomo Mitsui Trust Group Inc. Buys 167,596 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
The Oncology Bet Is Already Paying Off For Pfizer - Benzinga
Health Care Down as Vaccine Makers Slide -- Health Care Roundup - Marketscreener.com
Moderna Inc (MRNA) Stock Price, Trades & News - GuruFocus.com
Moderna Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Lawsuits Mount Over Moderna's RSV Vaccine - Law.com
February 2025 Options Now Available For Moderna (MRNA) - Nasdaq
Stock Watch: Q3, Bonfire Of The Vaccine Manufacturers - Citeline News & Insights
Brian M. Alexander Joins Valo Health as Chief Executive Officer and Flagship Pioneering as CEO-Partner - Quantisnow
OVERSEA CHINESE BANKING Corp Ltd Has $1.84 Million Stake in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Principal Financial Group Inc. Purchases 15,218 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna's SWOT analysis: mRNA pioneer faces pivotal moment as stock outlook shifts - Investing.com
Moderna Inc. stock outperforms competitors on strong trading day - MarketWatch
Moderna Stock Outlook: Is Wall Street Bullish or Bearish? - Nasdaq
Healthcare Marketing Impact Awards2024 - Modern Healthcare
모더나 (MRNA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.45%
1.11%
자본화:
|
볼륨(24시간):